British T-cell therapy anticancer drug company: Adaptimmune (ADAP) (2008)

Adaptimmune Therapeutics PLC (NASDAQ: ADAP) was established in 2008 and is headquartered in Abingdon, Oxon, United Kingdom, with 335 full-time employees. It is a company specializing in T-cell therapy [see Note 1] A genetic engineering company that treats cancer.

adaptimmune logo

Adaptimmune Therapeutics (ADAP):

Founded in 2008 by CEO James Noble and co-founder David M. Mott, Elliott Sigal is equal to Jonathan Knowles, the current chairman of the board of directors (see details).

Since its inception, Adaptimmune has focused on the use of T cell therapy to treat cancer. The principle is to use the body’s own immune mechanism-T cells to locate and kill cancer cells. Increased T cell receptor (TCR) sensitivity through the use of engineered methods to enhance the patient’s T cell response and overcome cancer tolerance. Simply put, it is to use T cell technology to locate and weaken cancer cells while strengthening the patient’s normal tissues to combat and treat cancer.

Specifically, cancer cells or virus-infected cells will have abnormal tissue-type molecules associated with cancer proteins on their surface, called HLA, which is equivalent to providing a “molecular fingerprint” for T cells, so that they can Quickly identify diseased cells from the immune system. However, most cancer target proteins come from normal proteins in the body, and T cells cannot recognize them, and they have a very low binding affinity. Adaptimmune’s technology is used to enable T cells to clearly distinguish the patient’s normal cells and cancer TCR, and then achieve the purpose of locating and killing cancer cells.

Adaptimmune’s alternative design program uses chimeric antibody receptors [Chimeric Antibody Receptors (CARs)] to improve T cells to achieve the purpose of enhancing effects. CARs use an engineered antibody fragment to recognize target cells. Once the antibody recognition fragment (such as CD19 B-cell protein) has bound to the target cell, it is artificially linked to several T cell receptors with the same protein domain (T cell designed to “switch the T cell on). Unlike CARs, Adaptimmune’s TCR can recognize cancer target proteins including intracellular and extracellular cancer targets, which significantly increases the breadth of targets.

Adaptimmune company patents:

  • Monoclonal TCRs – WO 2003/020763
  • Single chain MTCRs – WO 2004/033685
  • TCR Display – WO 2004/044004
  • High Affinity CDR2 Mutant TCRs – WO 2005/114215
  • mTCR Adoptive Therapy – WO 2006/000830
  • TCR Adoptive Therapy – WO 2008/038002
  • TCR Adoptive Therapy – WO 2008/039818
  • CD1-binding MTCRs – WO 2004/074322
  • High Affinity NY-ESO TCRs – WO 2005/113595
  • VYG HLA-A24 Telomerase TCRs – WO 2006/125962

Note 1: About T cells

T cell (T cell, T lymphocyte) is a type of lymphocyte, which plays an important role in immune response. T cells differentiate and mature in the thymus, and migrate to the surrounding lymphatic tissues after maturation. T is the abbreviation for “thymus” (thymus) instead of thyroid. The surface molecules of T cell membranes are related to the function of T cells and are also cell-surface markers of T cells, which can be used to separate and identify different subgroups of T cells.

Adaptimmune Therapeutics (ADAP) investment:

ADAP on 2015-05-06 landed on the US Nasdaq, 940 million shares issued, financing $ 150 million issue price of $ 17 / share, listed on the first day of break -5.88%. Same day IPO with COLL , LIFE , KLOX and HTGM .

ADRO , a newly listed company in the same industry , as well as leading anticancer drug companies such as BLCM , KITE , and JUNO , can all be paid attention to.

Notify of
Inline Feedbacks
View all Intels

Blank check company: Recharge Acquisition (RCHGU) (2020)

Blank Check Company: FS Development Corp. (FSDC) (2020)